Ocera Therapeutics Inc (NASDAQ:OCRX) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday, November 3rd, MarketBeat.com reports. They currently have a $1.75 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 2.94% from the company’s previous close.
Separately, Zacks Investment Research lowered Ocera Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. Ocera Therapeutics has a consensus rating of “Hold” and a consensus target price of $1.69.
Ocera Therapeutics (NASDAQ:OCRX) traded down $0.01 during trading on Friday, reaching $1.70. The company’s stock had a trading volume of 433,900 shares, compared to its average volume of 1,166,617. Ocera Therapeutics has a 12 month low of $0.52 and a 12 month high of $2.95.
COPYRIGHT VIOLATION WARNING: “Ocera Therapeutics Inc (NASDAQ:OCRX) Lowered to Neutral at HC Wainwright” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2017/11/14/ocera-therapeutics-inc-ocrx-downgraded-to-neutral-at-hc-wainwright.html.
An institutional investor recently raised its position in Ocera Therapeutics stock. Virtu KCG Holdings LLC lifted its stake in shares of Ocera Therapeutics Inc (NASDAQ:OCRX) by 194.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 213,531 shares of the biopharmaceutical company’s stock after acquiring an additional 141,040 shares during the period. Virtu KCG Holdings LLC owned 0.81% of Ocera Therapeutics worth $248,000 as of its most recent SEC filing. Institutional investors and hedge funds own 20.20% of the company’s stock.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.